Navigation Links
Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
Date:1/17/2012

HOBOKEN, N.J. and PHILADELPHIA, Jan. 17, 2012 /PRNewswire/ -- Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class small molecule that down-regulates GRP78, a key tumor survival and anti-apoptosis factor.

The NKP-1339 single agent dose escalation Phase I trial was conducted in patients with advanced solid tumors resistant to multiple, standard therapies. NKP-1339 was administered intravenously once weekly for 3 weeks followed by one week of no treatment. Thirty-four patients were treated, of which 30 were evaluable for dose determination. The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare in partnership with Translational Genomics Institute, and Dr. Howard Burris, at the Sarah Cannon Research Institute.

The NKP-1339 dose limiting toxicity was grade 2-3 nausea and grade 1-2 reversible renal insufficiency. At the recommended Phase II dose, NKP-1339 treatment was generally well tolerated and had manageable side effects. The most common drug-related side effects were grade 1 nausea, grade 1-2 vomiting and grade 1-2 fatigue. Infusional fever and chills were noted but prevented with steroid premedication.

"We reached our goal to determine the dose of NKP-1339 to take forward in future trials. Many toxicities commonly associated with other anticancer drugs, such as neutropenia, hepatotoxicity, neuropathy, rash, mucositis, diarrhea and alopecia, have not been seen to date," said Dr. Burris.

Anti-tumor activity, demonstrated by disease stability and/or tumor regression for 12-88+ weeks, was noted in patients with neuroendocrine tumors (NET), non-small cell lung cancer, sarcoma, colorectal and cancer of unknown primary. Three patients continue to receive NKP-1339 therapy on study.

"The preliminary read of NKP-1339 anti-tumor activity
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
3. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... Hill Studios, in partnership with the UCSF School of ... therapy games that have been specifically designed to help ... disease. Sue Lifschiz, a woman with Parkinson,s, will demonstrate ... levels to meet the needs of a variety of ...
... May 16, 2011 New Jersey Center for Prostate ... the nation to treat advanced prostate cancer patients with ... known as autologous cellular immunotherapies.  PROVENGE was approved by ... treatment of men with asymptomatic or minimally symptomatic metastatic ...
Cached Medicine Technology:Red Hill Studios/UCSF Partnership to Showcase 'Gaming Therapy' for People With Parkinson's Disease at Games for Health Conference 2Red Hill Studios/UCSF Partnership to Showcase 'Gaming Therapy' for People With Parkinson's Disease at Games for Health Conference 3New Jersey Center for Prostate Cancer & Urology Among First in Nation to Treat Advanced Prostate Cancer Patients with PROVENGE 2
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... least $50 billion in fuel costs now ... The current GHG standards are ... taken it upon themselves to install new ... , 1.    Idle reduction technologies , 2.    Efficient driveline ...
(Date:7/11/2014)... U.S. health officials have concluded that it,s highly unlikely ... a safety mishap last month. But, the U.S. ... a moratorium on the transfer of any dangerous germs ... report issued Friday, the CDC outlined several measures the ... doesn,t occur again. Last month, as many as 75 ...
(Date:7/11/2014)... 11, 2014 Alliance for Cancer ... non-profit dedicated exclusively to cell and gene therapies ... has joined the organization as Senior Development Officer. ... deep experience securing gifts and addressing influential donors. ... Giving Director for NewYork Presbyterian Hospital/Columbia University Medical ...
(Date:7/11/2014)... Biostimulants are widely applied in turf and ... These also help turf and ornamentals in absorption of ... ornamentals, and flowers appear healthy and strong as a ... from the last few years. The most dominating region ... with around 40% share in 2013, and is estimated ...
(Date:7/11/2014)... Miriam Hospital have found that people with mobility ... of smoking than those without mobility impairments. Additionally, ... attempt quitting than those without mobility impairments, and ... this population. The study and its findings are ... American Journal of Public Health . ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Miriam Hospital study examines smoking prevalence 2
... Steven Reinberg HealthDay Reporter , THURSDAY, June ... preschool program that sees them through elementary school have ... were not in preschool do, University of Minnesota researchers ... incomes, higher education levels, a higher socioeconomic status and ...
... 9, 2011From body builders to baby boomers, more Americans ... and maintenance in later life, satiety, weight loss and ... abreast of advancing research on the health benefits of ... Dairy Council of California and National Dairy Council are ...
... brain mechanism that could be targeted for new medications designed ... funded by the National Institute on Drug Abuse (NIDA), part ... subclass of brain nicotinic receptor is involved in nicotine,s ability ... the average weight gain after smoking is less than 10 ...
... , THURSDAY, June 9 (HealthDay News) -- With record-breaking ... States -- and with little relief in sight -- health ... posed by oppressive temperatures and humidity. "The elderly, young ... who are taking certain medications, especially antidepressants, are most ...
... June 9 (HealthDay News) -- Children are among those most ... toxocariasis (OT), which can lead to permanent vision loss, according ... occur when a person ingests dirt that,s contaminated with microscopic ... or cat. Larvae that emerge from the eggs migrate throughout ...
... treatments for Parkinson,s disease (PD) restore function for extended ... inaugural issue issue of the Journal of Parkinson,s ... platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and ... of PD. Parkinson,s disease is the second most ...
Cached Medicine News:Health News:Preschool's Benefits Linger Into Adulthood, Study Finds 2Health News:Preschool's Benefits Linger Into Adulthood, Study Finds 3Health News:From body builders to baby boomers: IFT session explores protein recommendations beyond muscle 2Health News:Potential new target for smoking cessation without weight gain 2Health News:Record Temperatures Posing Health Risks in U.S. 2Health News:Record Temperatures Posing Health Risks in U.S. 3Health News:Tainted Soil May Put Kids at Risk for Vision Loss 2Health News:New animal study shows promise for development of Parkinson's disease drug 2
Alpha prime immunoassay system features unsurpassed quality of results, full automation of EIA tests for microplate applications, complete walk-away, up to 18 different assays per run, photometric an...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
Medicine Products: